LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 09, 2024 | Last Trade: US$1.71 0.00 0.00

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.

David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

Contacts

ESSA Pharma, Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page